$8.94
0.89%
Nasdaq, Jul 03, 09:51 pm CET
ISIN
US09058V1035
Symbol
BCRX
Sector
Industry

BioCryst Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

BioCryst Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
89%
Hold
11%

BioCryst Pharmaceuticals, Inc. Price Target

Target Price $16.83
Price $8.94
Potential
Number of Estimates 15
15 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2026 . The average BioCryst Pharmaceuticals, Inc. target price is $16.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 16 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the BioCryst Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 450.71 626.68
36.00% 39.04%
EBITDA Margin -0.29% 16.01%
99.05% 5,650.67%
Net Margin -19.72% 4.13%
71.15% 120.94%

14 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2025 . The average BioCryst Pharmaceuticals, Inc. sales estimate is

$627m
Unlock
. This is
24.47% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$661m 31.36%
Unlock
, the lowest is
$588m 16.81%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $451m 36.00%
2025
$627m 39.04%
Unlock
2026
$710m 13.26%
Unlock
2027
$795m 11.97%
Unlock
2028
$876m 10.27%
Unlock
2029
$971m 10.77%
Unlock
2030
$1.1b 8.57%
Unlock
2031
$1.1b 6.07%
Unlock
2032
$1.2b 5.10%
Unlock

5 Analysts have issued an BioCryst Pharmaceuticals, Inc. EBITDA forecast 2025. The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is

$100m
Unlock
. This is
191.32% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$112m 226.22%
Unlock
, the lowest is
$89.2m 158.94%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-1.3m 98.71%
2025
$100m 7,817.69%
Unlock
2026
$130m 29.67%
Unlock
2027
$176m 35.63%
Unlock

EBITDA Margin

2024 -0.29% 99.05%
2025
16.01% 5,650.67%
Unlock
2026
18.33% 14.49%
Unlock
2027
22.20% 21.11%
Unlock

15 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average BioCryst Pharmaceuticals, Inc. net profit estimate is

$25.9m
Unlock
. This is
148.40% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$76.9m 243.78%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-88.9m 60.77%
2025
$25.9m 129.12%
Unlock
2026
$75.0m 189.80%
Unlock
2027
$133m 76.73%
Unlock
2028
$262m 98.02%
Unlock
2029
$331m 26.18%
Unlock
2030
$398m 20.23%
Unlock
2031
$488m 22.59%
Unlock
2032
$531m 8.85%
Unlock

Net Margin

2024 -19.72% 71.15%
2025
4.13% 120.94%
Unlock
2026
10.57% 155.93%
Unlock
2027
16.68% 57.81%
Unlock
2028
29.95% 79.56%
Unlock
2029
34.12% 13.92%
Unlock
2030
37.78% 10.73%
Unlock
2031
43.66% 15.56%
Unlock
2032
45.22% 3.57%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.43 0.12
63.56% 127.91%
P/E 72.27
EV/Sales 3.82

15 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. EPS is

$0.12
Unlock
. This is
146.15% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.37 242.31%
Unlock
, the lowest is
$0.00 100.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.43 63.56%
2025
$0.12 127.91%
Unlock
2026
$0.36 200.00%
Unlock
2027
$0.63 75.00%
Unlock
2028
$1.25 98.41%
Unlock
2029
$1.58 26.40%
Unlock
2030
$1.90 20.25%
Unlock
2031
$2.33 22.63%
Unlock
2032
$2.54 9.01%
Unlock

P/E ratio

Current -34.38 461.95%
2025
72.27 310.18%
Unlock
2026
24.94 65.49%
Unlock
2027
14.11 43.42%
Unlock
2028
7.13 49.47%
Unlock
2029
5.65 20.76%
Unlock
2030
4.70 16.81%
Unlock
2031
3.83 18.51%
Unlock
2032
3.52 8.09%
Unlock

Based on analysts' sales estimates for 2025, the BioCryst Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.76 4.99%
2025
3.82 19.68%
Unlock
2026
3.38 11.71%
Unlock
2027
3.01 10.69%
Unlock
2028
2.73 9.32%
Unlock
2029
2.47 9.72%
Unlock
2030
2.27 7.89%
Unlock
2031
2.14 5.72%
Unlock
2032
2.04 4.85%
Unlock

P/S ratio

Current 3.72 3.53%
2025
2.99 19.66%
Unlock
2026
2.64 11.71%
Unlock
2027
2.35 10.69%
Unlock
2028
2.13 9.32%
Unlock
2029
1.93 9.72%
Unlock
2030
1.77 7.89%
Unlock
2031
1.67 5.72%
Unlock
2032
1.59 4.85%
Unlock

Current BioCryst Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B of A Securities
Locked
Locked
Locked Jul 01 2025
RBC Capital
Locked
Locked
Locked Jun 30 2025
Wedbush
Locked
Locked
Locked Jun 30 2025
Needham
Locked
Locked
Locked Jun 27 2025
Needham
Locked
Locked
Locked Jun 25 2025
Barclays
Locked
Locked
Locked May 07 2025
HC Wainwright & Co.
Locked
Locked
Locked May 06 2025
Analyst Rating Date
Locked
B of A Securities:
Locked
Locked
Jul 01 2025
Locked
RBC Capital:
Locked
Locked
Jun 30 2025
Locked
Wedbush:
Locked
Locked
Jun 30 2025
Locked
Needham:
Locked
Locked
Jun 27 2025
Locked
Needham:
Locked
Locked
Jun 25 2025
Locked
Barclays:
Locked
Locked
May 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today